The poathologic complete response or minimal residual disease rate was 30% in ELAP-treated patients and 16% in EL-treated patients; tumor ERG positivity, or PTEN loss, was associated with more extensive residual tumors at radical prostatectomy [209]. This evidence concerns the gene ERG and neoplasm.